Clinical Trials Logo

Clinical Trial Details — Status: Completed

Administrative data

NCT number NCT05917249
Other study ID # Ms-399-2022
Secondary ID
Status Completed
Phase N/A
First received
Last updated
Start date June 7, 2023
Est. completion date January 30, 2024

Study information

Verified date February 2024
Source Cairo University
Contact n/a
Is FDA regulated No
Health authority
Study type Interventional

Clinical Trial Summary

Peripheral neuropathy increases the prevalence of diabetic foot ulcers following a decrease in foot sensation. Therefore, the treatment of this disorder is very important.


Description:

The current study aimed to investigate the efficacy of TECAR therapy on lower limb perfusion index (PI) and to evaluate the efficacy of TECAR therapy in improving the peripheral vascularity, reducing foot pain, and improving the tactile sensation of the soles in diabetic peripheral neuropathy (DPN) patients. twenty three diabetic neuropathy patients were included in the study and underwent 12 sessions of Capacitive TECAR therapy over one month. Pain, tactile sensation of the sole and PI were evaluated at the start and after each session till the end of the study.


Recruitment information / eligibility

Status Completed
Enrollment 23
Est. completion date January 30, 2024
Est. primary completion date January 1, 2024
Accepts healthy volunteers No
Gender All
Age group 40 Years to 70 Years
Eligibility Inclusion Criteria: - Age 40-70 years - Type II DM with DPN (grade I-II) in lower limbs - Duration of DM>5 years - Visual Analog Scale (VAS) =3 in the feet - Sensory impairments in the lower extremities Exclusion Criteria: - Patient with previous stenting or surgical intervention of lower limb arterial system. - Patients with previous history of DVT. - Pregnancy - Diabetic infectious wound - Cardiac pacemaker presence - Severe liver and kidney dysfunction or history of heart and lung disease.

Study Design


Intervention

Device:
Capacitive-Resistive Noninvasive Radiofrequency
The two passive plates were under the back of the patient. The active capacitive plates of the machine (CAPENGERY, C200, Spain) will be applied initially for 20 minutes over the sole of both feet, with the machine adjusted on the A-thermal mode (37 oC). During the remaining 20 minutes, active capacitive plates are relocated over femoral vessels at the femoral triangle with the machine adjusted on the frank thermal mode (41 oC).

Locations

Country Name City State
Egypt Medicine Cairo

Sponsors (1)

Lead Sponsor Collaborator
Cairo University

Country where clinical trial is conducted

Egypt, 

References & Publications (2)

Niajalili M, Sedaghat M, Reazasoltani A, Akbarzade Baghban AR, Sadat Naimi S. [Effect of Capacitive Tecar Therapy on Foot Pain and Tactile Sensation in Patients With Type 2 Diabetes (Persian)]. Archives of Rehabilitation. 2020; 21(3):304-319. https://doi.org/10.32598/RJ.21.3.60.5

Tashiro Y, Hasegawa S, Yokota Y, Nishiguchi S, Fukutani N, Shirooka H, Tasaka S, Matsushita T, Matsubara K, Nakayama Y, Sonoda T, Tsuboyama T, Aoyama T. Effect of Capacitive and Resistive electric transfer on haemoglobin saturation and tissue temperature. Int J Hyperthermia. 2017 Sep;33(6):696-702. doi: 10.1080/02656736.2017.1289252. Epub 2017 Feb 19. — View Citation

Outcome

Type Measure Description Time frame Safety issue
Primary Change of the perfusion index at the end of the first session compared to baseline readings. the perfusion index readings will be taken before the first session and set as baseline reading and after the first session and the change will be calculated.The Masimo SET "Mighty-Sat Fingertip Pulse Oximetry" (Masimo Corporation, Irvine, CA, USA model 9900) was attached to the big toe of each patient. the reading will be the the mean of three measurements of perfusion index (PI) taken at one-minute intervals. 40 minutes
Secondary Visual Analogue Scale Patient defines the degree of pain on a visual scale without numeric values, while the values are visible on the back side for the registrar where 0 indicates no pain and 10 indicates the most unbearable pain. The test was performed before intervention, after each session and one month after the end of all twelve sessions. 2 months
Secondary Tactile sensation of the sole Tactile sensation of the sole using Semmes-Weinstein monofilament 5.07/10 g. the test will be performed after each session. 2 months
Secondary Analgesic effect Analgesic effect after each session; will be evaluated using the four grades of WHO evaluation criteria for pain relief:
Complete remission (CR)
Partial remission (PR)
Mild remission (MR)
No response (NR).
2 months
Secondary The total remission rate 2 months
See also
  Status Clinical Trial Phase
Completed NCT04988321 - Theta Burst Brain Stimulation in Diabetic Neuropathy Patients With Neuropathic Pain: Investigating Neural Mechanisms N/A
Completed NCT00385671 - An Open-Label Comparison of Duloxetine to Other Alternatives for the Management of Diabetic Peripheral Neuropathic Pain Phase 4
Completed NCT00159679 - Pregabalin in the Treatment of Pain Due to Diabetic Peripheral Neuropathy Phase 4
Completed NCT00141401 - Safety and Efficacy of Pregabalin in Patients With Diabetic Peripheral Neuropathy. Phase 3
Active, not recruiting NCT04469270 - Study to Assess Safety and Efficacy of Engensis in Painful Diabetic Peripheral Neuropathy Phase 3
Completed NCT00553475 - Randomized, Double-Blind, Multicenter, Placebo-Controlled Study Of Pregabalin For Pain Associated With Diabetic Peripheral Neuropathy Phase 3
Completed NCT00381719 - Safety and Efficacy of AGN 203818 in Patients With Painful Diabetic Peripheral Neuropathy Phase 2
Completed NCT00539175 - Treatment of Painful Diabetic Neuropathy With Photon Stimulation N/A
Completed NCT00058968 - A Study for the Treatment of Painful Diabetic Neuropathy Phase 3
Completed NCT05029297 - Study With Two Capsaicin Topic Treatments in Diabetic Neuropathy. Phase 3
Completed NCT02215252 - A Clinical Trial To Evaluate PF-05089771 On Its Own And As An Add-On Therapy To Pregabalin (Lyrica) For The Treatment Of Pain Due To Diabetic Peripheral Neuropathy (DPN) Phase 2
Completed NCT00785577 - A Study for Treatment of Pain in Patients With Diabetic Neuropathy. Phase 2
Completed NCT00858351 - Thermal Biofeedback for the Treatment of Diabetic Neuropathy N/A
Completed NCT03047278 - Transporters for Organic Cations and Glycemic Control in Patients With Neuropathic Pain. Phase 4
Completed NCT01628627 - Frequency Modulated Neural Stimulation (FREMS) in Symptomatic Diabetic Neuropathy Phase 4
Completed NCT03315598 - Evaluation of an Effectiveness and Safety of the Electroacupuncture in the Management of Intractable Neuropathic Pain N/A
Completed NCT01057693 - Study Of Pregabalin (Lyrica) In Patients With Painful Diabetic Peripheral Neuropathy Phase 3
Completed NCT01564459 - Study to Evaluate MK-6096 in the Treatment of Painful Diabetic Neuropathy (PDN) in Adults (MK-6096-021) Phase 2
Recruiting NCT01214590 - Preliminary Assessment of the Efficacy of the VascuActiveâ„¢ Device on Diabetic Peripheral Neuropathy N/A
Completed NCT01089556 - A Study in Painful Diabetic Neuropathy Phase 3